drugset / Trial / NCT00312650
Doxil and Gemcitabine in Recurrent Ovarian Cancer
Phase 2
Terminated
24 enrolled
Women and Infants Hospital of Rhode Island
Ortho Biotech, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Standard treatment for recurrent ovarian cancer is chemotherapy with one or more drugs. One of these drugs, Doxil, can cause skin toxicity at the standard dosages. This study investigates using a lower dose given more frequently in combination with a second drug Gemcitabine.
Timeline
- Start
- 2006-04
- Primary completion
- 2006-05
- Completion
- 2006-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | — | — |
| Subject | Gemcitabine | Small molecule | — | — |